Navigation Links
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
Date:8/1/2014

SAN DIEGO, Aug. 1, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2014.

"We have continued to see encouraging advancements in the US commercialization of BELVIQ, including a 43% quarter-over-quarter increase in estimated total prescriptions and estimated total per week prescriptions surpassing the 10,000 mark," said Jack Lief, Arena's President and Chief Executive Officer. "Other recent notable achievements consist of advancing our internally discovered pipeline and lorcaserin life-cycle management programs, and establishing a marketing and supply agreement for BELVIQ in Israel."

Second Quarter and Recent DevelopmentsBELVIQ® (lorcaserin HCl) CIV US Commercial Update

  • IMS Health estimates that approximately 110,000 prescriptions for BELVIQ were filled in the second quarter of 2014, representing growth of approximately 43% in total prescriptions as compared to the previous quarter.
  • Eisai recorded net product sales for BELVIQ of $9.9 million in the second quarter of 2014.
  • Eisai completed its planned increase of more than 200 new sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ by 50% to approximately 600. Eisai expects this further expansion of the sales force will enable them to increase their reach to a total of approximately 92,000 physicians in the United States.
  • BELVIQ Additional Developments

  • Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Teva Pharmaceutical Industries Ltd.'s local Israeli subsidiary entered into a marketing and supply agreement for BELVIQ in Israel. Under the agreement, Arena granted the rights to market and distribute BELVIQ in the territory for weight loss or weight management in obese and overwei
    '/>"/>

  • SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity
    2. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1
    3. Healthcare Companies Announce Drug Launches, Upcoming Conference Calls, and Financial Results Schedules - Research Report on Bristol-Myers Squibb, Teva, Jazz, AmerisourceBergen and Arena
    4. Arena Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
    5. Arena Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
    6. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
    7. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7
    8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
    9. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Global Healthcare Conference
    10. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
    11. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today reported financial results for ... Global revenue for the Company,s Urgent ®  PC ... quarterly revenue record, as compared to $3.9 million in ...
    (Date:1/22/2015)... 22, 2015  Amgen (NASDAQ: AMGN ) today announced that ... results on Tuesday, Jan. 27, 2015, after the close of the ... call with the investment community at 2 p.m. PT. Participating in ... chairman and chief executive officer, and other members of Amgen,s senior ...
    (Date:1/22/2015)... , Jan. 22, 2015 Increasing sophistication among enterprise ... of localization purchasing in 2015, says Moravia ... a recent study by market research firm Common Sense ... solution for their translation and localization needs. "From a ...
    Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
    ... on Glucose Homeostasis Effects in,Normal and Diabetic Rats ... a 14-day,Phase IIa study of the safety profile ... selective inhibitor of,the Sodium-Glucose Transporter 2 (SGLT2) administered ... 2 diabetes, no,discontinuations due to adverse events and ...
    ... LOUISVILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/ --,Replidyne, ... I trials,studying REP8839, a novel topical antibiotic ... major skin pathogens including,methicillin-resistant S. aureus (MRSA). ... that topically applied REP8839 appears safe,well-tolerated and ...
    Cached Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4
    (Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
    (Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
    (Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
    (Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
    (Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
    Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
    ... Available at ... PhillyHealthInfo.org, PHILADELPHIA, Oct. 9 PhillyHealthInfo is the ... Chester,Delaware, and Montgomery counties. Go to http://www.PhillyHealthInfo.org ,for this season,s flu ... Where to go for free or low cost flu shots. -- ...
    ... -- Nurses and physicians at Nationwide Childrens Hospital are using ... extreme pain of dressing changes and wound care. Instead ... Childrens Hospital Burn Center is now using virtual reality games ... wounds. , Its long been known that the ...
    ... Nurse Savvy Research Group is,an exciting newcomer ... an online medical information service established to,provide the ... which,doctors they would choose for a variety of ... data gathered for the website will be,obtained through ...
    ... 9, 2007 Chairman of the,Board and Chief Executive ... PG ) shareholders at its annual meeting today. ... the short, mid and long term,-- consistently, reliably and ... the company,s results for fiscal 2007. P&G increased,net sales ...
    ... UPCARE(R) E2E, an end-to-end, financial and clinical ... for laboratories. -- ... Mich., Oct. 9 Today, UPCARE Technology, Inc.,unveiled its new ... part on the success of its parent company, Marquette,General Health ...
    ... three scientists receiving the 2007 Nobel Prize for Physiology or ... their careers, bringing to 42 the number of Nobel Laureates ... Capecchi, Ph.D. of the University of Utah and Oliver Smithies, ... with Sir Martin J. Evans of Cardiff University in Wales ...
    Cached Medicine News:Health News:Virtual game helps children escape realities of burn unit 2Health News:Nursesavvy.com Promoting Quality Healthcare for Everyone 2Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 2Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 3Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 4Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 5Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 6Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 2Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 3Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 4
    The flexible EXXCEL ePTFE Vascular Access Graft material is designed to offer textile-like handling characteristics-cuts neatly for a clean edge, retains fully open lumen shape, and sutures smoothly....
    ... intended for monitoring the accuracy and precision of ... in vitro diagnostic use only. Provided in a ... up to ten days stability at 2 ... used in accordance with the directions accompanying the ...
    PowerMed is a billing software....
    Managed care is a billing and tracking system....
    Medicine Products: